Consensus Document on Prevention and Treatment of Tuberculosis in Patients for Biological Treatment;Documento de consenso sobre la prevención y el tratamiento de la tuberculosis en pacientes candidatos a tratamiento biológico

Archivos de Bronconeumologia

Volumn 52, Issue 1, 2016, Pages 36-45

  Mir Viladrich, Isabel ^a   Daudén Tello, Esteban ^b   Solano López, Guillermo ^b   López Longo, Francisco Javier ^c   Taxonera Samso, Carlos ^d   Sánchez Martínez, Paquita ^e   Martínez Lacasa, Xavier ^f   García Gasalla, Mercedes ^a   Dorca Sargatal, Jordi ^g   Arias Guillén, Miguel ^h   García García, José Maria ⁱ  

^a HOSPITAL SON LLÀTZER   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e HOSPITAL DEL MAR   (Spain)

^f HOSPITAL MÚTUA DE TERRASSA   (Spain)

^g HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^h HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

ⁱ HOSPITAL SAN AGUSTÍN   (Spain)

Author keywords

Biologic therapies; Chronic inflammatory diseases; Interferon gamma release assays; Latent tuberculosis infection

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ABATACEPT; ADALIMUMAB; ANAKINRA; BELIMUMAB; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; ISONIAZID; RIFAMPICIN; RITUXIMAB; TOCILIZUMAB; USTEKINUMAB;

ARTICLE; BIOLOGICAL THERAPY; CONSENSUS DEVELOPMENT; HEALTH CARE PLANNING; HUMAN; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; PREVENTIVE MEDICINE; TREATMENT DURATION; TUBERCULIN TEST; IMMUNOSUPPRESSIVE TREATMENT; PRACTICE GUIDELINE; CLINICAL PRACTICE; CROHN DISEASE; DRUG EFFICACY; FOLLOW UP; INFECTION PREVENTION; INFECTION RISK; MYCOBACTERIUM TUBERCULOSIS TEST KIT; PSORIASIS; RHEUMATIC DISEASE; TREATMENT INDICATION; ULCERATIVE COLITIS;

BIOLOGICAL THERAPY; HUMANS; IMMUNOSUPPRESSION; LATENT TUBERCULOSIS; PRACTICE GUIDELINES AS TOPIC;

EID: 84957904692     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbr.2015.11.005     Document Type: Article

References (121)

1. Infliximab approval process in Crohn's disease. Department of Health and Human Services. Public Health Service. Food and Drug Administration August 24, 1998.
2. Furst D.E., Keystone E.C., Fleischmann R., Mease P., Breedveld F.C., Smolen J.S., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 2010, 69(Suppl 1):12-29.
3. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor-alpha neutralizing agent. N Engl J Med 2001, 345:1098-1104.
4. Gomez-Reino J.J., Carmona L., Valverde V.R., Mola E.M., Montero M.D. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis Rheum 2003, 48:2122-2127.
5. Obrador A., Lopez San Roman A., Munoz P., Fortun J., Gassull M.A. Consensus guideline on tuberculosis and treatment of inflammatory bowel disease with infliximab. Spanish Working Group on Crohn Disease and Ulcerative Colitis. Gastroenterol Hepatol 2003, 26:29-33.
6. Gardam M.A., Keystone E.C., Menzies R., Manners S., Skamene E., Long R., et al. Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management. Lancet Infect Dis 2003, 3:148-155.
7. Carmona L., Gomez-Reino J.J., Rodriguez-Valverde V., Montero D., Pascual-Gomez E., Mola E.M., et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005, 52:1766-1772.
8. Jauregui-Amezaga A., Turon F., Ordás I., Gallego M., Feu F., Ricart E., et al. Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening. J Crohns Colitis 2013, 7:208-212.
9. Gross P.A., Barrett T.L., Dellinger P., Krause P.J., Martone W.J., McGowan J.E., et al. Purpose of quality standards for infectious diseases. Clin Infect Dis 1994, 18:421.
10. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., Tak P.P. Tumor necrosis factor antagonists mechanisms of action: a comprehensive review. Pharmacol Therapeut 2008, 117:92-101.
11. Fonseca J.E., Santos M.J., Canhao H., Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009, 8:538-542.
12. Rosman Z., Shoenfeld Y., Zandman-Goddard G. Biologic therapy for autoimmune diseases: An update. BMC Medicine 2013, 11:88.
13. Pieper J., Herrath J., Raghavan S., Muhammad K., van Vollenhoven R., Malmström V. CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients. BMC Immunol 2013, 14:34.
14. Benson J.M., Peritt D., Scallon B.J., Heavner G.A., Shealy D.J., Giles-Komar J.M., et al. Discovery and mechanism of ustekinumab: A human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs 2011, 3:535-545.
15. Maini R., St Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354:1932-1939. for the ATTRACT Study Group.
16. Smolen J.S., van der Heijde D.M., St Clair E.W., Emery P., Bathon J.M., Keystone E., et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial. Arthritis Rheum 2006, 54:702-710. for Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group.
17. Antoni C.E., Kavanaugh A., Kirkham B., Tutuncu Z., Burmester G.R., Schneider U., et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). ArthritisRheum 2005, 52:1227-1236.
18. Hoff M., Kavanaugh A., Haugeberg G. Hand bone loss in patients with psoriatic arthritis: Posthoc analysis of IMPACT II data comparing infliximab and placebo. J Rheumatol 2013, 40:1344-1348.
19. Van der Heijde D., Dijkmans B., Geusens P., Sieper J., deWoody K., Williamson P., et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005, 52:582-591. for the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group.
20. Cantini F., Niccoli L., Nannini C., Kaloudi O., Cassarà E., Susini M., et al. Efficacy of infliximab in refractory Behçet's disease-associated and idiopathic posterior segmentuveitis: A prospective, follow-up study of 50 patients. Biologics 2012, 6:5-12.
21. Okada A.A., Goto H., Ohno S., Mochizuki M. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol 2012, 130:592-598. for Ocular Behçet's disease research group of Japan.
22. Moreland L.W., Weinblatt M.E., Keystone E.C., Kremer J.M., Martin R.W., Schiff M.H., et al. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. Arthritis Rheum 2008, 59:32-861.
23. Lovell D.J., Reiff A., Jones O.Y., Schneider R., James N., Stein L.D., et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006, 54:1987-1994.
24. Mease P.J., Kivitz A.J., Burch F.X., Siegel E.L., Cohen S.B., Ory P., et al. Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. Arthritis Rheum 2004, 50:2264-2272.
25. Horneff G., Burgos-Vargas R., Constantin T., Foeldvari I., Vojinovic J., Chasnyk V.G., et al. for the Paediatric Rheumatology International Trials Organisation (PRINTO). Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis 2013, 0:1-9.
26. Brandt J., Listing J., Haibel H., Sorensen H., Schwebig A., Rudwaleit M., et al. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford) 2005, 44:342-348.
27. Cohen S.B., Moreland L.W., Cush J.J., Greenwald M.W., Block S., Shergy W.J., et al. A multicenter double-blind randomized placebo-controlled trial of Kineret (anakinra), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate therapy. Ann Rheum Dis 2004, 63:1062-1068.
28. Weinblatt M.E., Keystone E.C., Furst D.E., Moreland L.W., Weisman M.H., Birbara C.A., et al. Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody for the treatment of RA in patients taking concomitant methotrexate. The ARMADA trial. Arthritis Rheum 2003, 48:35-45.
29. Breedveld F.C., Weisman M.H., Kavanaugh A.F., Cohen S.B., Pavelka K., van Vollenhovenet R., et al. The PREMIER Study: Combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in methotrexate-naïve patients with early, aggressive rheumatoid arthritis. Arthritis Rheum 2006, 54:26-37. for the PREMIER investigators.
30. Lovell D.J., Ruperto N., Goodman S., Reiff A., Jung L., Jarosova K., et al. Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008, 359:810-820. for the Pediatric Rheumatology Collaborative Study Group.
31. Mease P.J., Gladman D.D., Ritchlin C.T., Ruderman E.M., Steinfeld S.D., Choy E.H.S., et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. ADEPT. Arthritis Rheum 2005, 52:3279-3289. for the ADEPT Study Group.
32. Van der Heijde D., Kivitz A., Schiff M.H., Sieper J., Dijkmans B.A.C., Braun J., et al. Long-term efficacy and safety in Ankylosing Spondylitis Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ATLAS). Arthritis Rheum 2006, 54:2136-2146. for the Adalimumab Trial Evaluating.
33. Gomez-Reino J.J., Maneiro J.R., Ruiz J., Roselló R., Sanmarti R., Romero A.B., et al. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: The MIRAR Study. Ann Rheum Dis 2012, 71:1861-1864.
34. López-Longo F.J. Rituximab en el lupus eritematoso sistémico y otras enfermedades autoinmunes. Med Clin Monogr (Barc) 2008, 9:15-19.
35. Fernandez-Nebro A., Marenco de la Fuente J.L., Carreño L., Galindo Izquierdo M., Tomero E., Rúa-Figueroa I., et al. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: The LESIMAB study. Lupus 2012, 21:1063-1076.
36. Genovese M.C., Becker J.C., Schiff M., Luggen M., Sherrer Y., Kremer J., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005, 353:1114-1123.
37. Ruperto N., Lovell D.J., Quartier P., Paz E., Rubio-Perez N., Silva C.A., et al. Abatacept in children with juvenile idiopathic arthritis: A randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008, 372:383-391. for the PRINTO Pediatric Rheumatology Collaborative Study Group.
38. Fleischmann R.M., Halland A.M., Brzosko M., Burgos-Vargas R., Mela C., Vernon E., et al. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results. J Rheumatol 2013, 40:113-126.
39. De Benedetti F., Brunner H.I., Ruperto N., Kenwright A., Wright S., Calvo I., et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012, 367:2385-2395.
40. Smolen J.S., Kay J., Doyle M.K., Landewé R., Matteson E.L., Wollenhaupt J., et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): A multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009, 374:210-221. GO-AFTER study investigators.
41. Wagner C.L., Visvanathan S., Elashoff M., McInnes I.B., Mease P.J., Krueger G.G., et al. Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. Ann Rheum Dis 2013, 72:83-88.
42. Braun J., Baraliakos X., Hermann K.G., Deodhar A., van der Heijde D., Inman R., et al. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: Results through 4 years of the GO-RAISE trial. Ann Rheum Dis. 2014, 73:1107-1113.
43. Van Vollenhoven R.F., Cifaldi M.A., Ray S., Chen N., Weisman M.H. American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: Data from a 52-week phase III trial. Arthritis Care Res (Hoboken) 2011, 63:128-134.
44. Petri M.A., van Vollenhoven R.F., Buyon J., Levy R.A., Navarra S.V., Cervera R., et al. Baseline predictors of systemic lupus erythematosus flares: Data from the combined placebo groups in the phase III Belimumab trials. Arthritis Rheum 2013, 65:2143-2153. for the BLISS-52 and BLISS-76 Study Groups.
45. Rutgeerts P., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004, 126:402-413.
46. Sands B.E., Anderson F.H., Bernstein C.N., Chey W.Y., Feagan B.G., Fedorak R.N., et al. Infliximab maintenance therapy for fistulising Crohn's disease. N Engl J Med 2004, 350:876-885.
47. Lichtenstein G.R., Yan S., Bala M., Hanauer S. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004, 99:91-96.
48. Lichtenstein G.R., Yan S., Bala M., Blank M., Sands B. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulising Crohn's disease. Gastroenterology 2005, 128:862-869.
49. Feagan B.G., Yan S., Bala M., Bao W., Lichtenstein G.R. The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol 2003, 98:2232-2238.
50. Rutgeerts P., Diamond R.H., Bala M., Olson A., Lichtenstein G.R., Bao W., et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006, 63:433-442.
51. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
52. Feagan B.G., Reinisch W., Rutgeerts P., Sandborn W.J., Yan S., Eisenberg D., et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007, 102:794-802.
53. Hyams J., Crandall W., Kugathasan S., Griffiths A., Olson A., Johanns J., et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007, 132:863-873. REACH Study Group.
54. Hyams J., Damaraju L., Blank M., Johanns J., Guzzo C., Winter H.S., et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol 2012, 10:391-399. T72 Study Group.
55. Regueiro M., Schraut W., Baidoo L., Kip K.E., Sepulveda A.R., Pesci M., et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009, 136:441-450.
56. Viazis N., Giakoumis M., Koukouratos T., Anastasiou J., Katopodi K., Kechagias G., et al. Long term benefit of one year infliximab administration for the treatment of chronic refractory pouchitis. J Crohns Colitis 2013, 7:457-460.
57. Sandborn W.J., Hanauer S.B., Rutgeerts P., Fedorak R.N., Lukas M., Panaccione R., et al. Adalimumab for maintenence treatment of Crohn's disease: Results of the CLASSIC II trial. Gut 2007, 56:1232-1239.
58. Colombel J.F., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
59. Feagan B.G., Panaccione R., Sandborn W.J., D'Haens G.R., Schreiber S., Rutgeerts P.J., et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008, 135:1493-1499.
60. Rutgeerts P., van Assche G., Sandborn W.J., Wolf D.C., Geboes K., Colombel J.F., et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: Data from the EXTEND trial. Gastroenterology 2012, 142:1102-1111.
61. Reinisch W., Sandborn W.J., Hommes D.W., D'Haens G., Hanauer S., Schreiber S., et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Results of a randomised controlled trial. Gut 2011, 60:780-787.
62. Sandborn W.J., van Assche G., Reinisch W., Colombel F.J., d'Haens G., Douglas C. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012, 142:257-265.
63. Feagan B.G., Sandborn W.J., Lazar A., Roopal B., Thakkar Huang B., Reilly N., et al. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology 2014, 146:110-118.
64. Hyams J.S., Griffiths A., Markowitz J., Baldassano R.N., Faubion W.A., Colletti R.B., et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology 2012, 143:365-374.
65. Savarino E., Bodini G., Dulbecco P., Assandri L., Bruzzone L., Mazza F., et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: A randomized controlled trial. Am J Gastroenterol 2013, 108:1731-1742.
66. Sandborn W.J., Feagan B.G., Marano C., Zhang H., Strauss R., Johanns J., et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014, 146:85-95. PURSUIT-SC Study Group.
67. Sandborn W.J., Feagan B.G., Marano C., Zhang H., Strauss R., Johanns J., et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014, 146:96-109.
68. Sandborn W.J., Feagan B.G., Stoinov S., Honiball P.J., Rutgeerts P., Mason D., et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007, 357:228-238.
69. Schreiber S., Khaliq-Kareemi M., Lawrance I.C., Thomsen O.Ø., Hanauer S.B., McColm J., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007, 357:239-250.
70. European Medicines Agency. Ficha técnica de Humira (adalimumab) [consultado 29 Oct 2013]. Disponible en: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000481/WC500050870.pdf.
71. European Medicines Agency. Ficha técnica de Enbrel (etanercept) [consultado 29 Oct 2013]. Disponible en: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000262/WC500027361.pdf.
72. European Medicines Agency. Ficha técnica de Remicade (infliximab) [consultado 29 Oct 2013]. Disponible en: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000240/WC500050888.pdf.
73. European Medicines Agency. Ficha técnica de Stelara (ustekinumab) [consultado 29 Oct 2013]. Disponible en:http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000958/WC500058513.pdf.
74. Ara M., Dauden E. Etanercept for the treatment of psoriasis. Expert Rev Dermatol 2013, 8:357-372.
75. Rott S., Mrowietz U. The use of infliximab in dermatology. J Dtsch Dermatol Ges 2007, 5:655-660.
76. Warren R.B., Griffiths C.E. The future of biological therapies. Semin Cutan Med Surg 2010, 29:63-66.
77. Tsuda K., Yamanaka K., Kondo M., Matsubara K., Sasaki R., Tomimoto H., et al. Ustekinumab improves psoriasis without altering T cell cytokine production, differentiation, and T cell receptor repertoire diversity. PLoS One 2012, 7:e51819.
78. Sichletidis L., Settas L., Spyratos D. TB in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006, 10:1127-1132.
79. Hamilton C. TB in the cytokine era: What rheumatologist need to know. Arthritis Rheum 2003, 48. 2085- 2085.
80. ® test for detecting latent tuberculosis in patients considered as candidates for anti-TNF therapy in routine clinical practice. Enferm Infecc Microbiol Clin 2013, 31:76-81.
81. Ponce de Leon D., Acevedo-Vasquez E., Sanchez-Torres A., Cucho M., Alfaro J., Perich R. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: Study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005, 64:1360-1361.
82. Ponce de Leon D., Acevedo-Vasquez E., Alvizuri S., Gutierrez C., Cucho M., Alfaro J., et al. Comparison of an interferon-γ assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 2008, 35:776-781.
83. Huebner R.E., Schein M.F., Bass JB The tuberculin skin test. Clin Infect Dis 1993, 17:968-975.
84. Cellestis. Quantiferon-TB Gold. 2009 [consultado 20 Oct 2009]. Disponible en: http://www.cellestis.com/.
85. Oxford Immunotec. T.Spot-TB. 2009 [consultado 20 Oct 2009]. Disponible en: http://www.oxfordimmunotec.com/.
86. Dominguez J., De Souza-Galvao M., Ruiz-Manzano J., Latorre I., Prat C., Lacoma A., et al. Comparison of two commercially available gamma-interferon blood tests for immunodiagnosis of tuberculosis. Clin Vaccine Immunol 2008, 15:168-171.
87. Mazurek G.H., Jereb J., Vernon A., LoBue P., Goldberg S., Castro K. Updated guidelines for using interferon g release assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 2010, 59:1-25.
88. European Centre for Disease Prevention and Control (ECDC). Use of interferon-gamma release assays in support of TB diagnosis [consultado Jul 2013]. Disponible en: http://ecdc.europa.eu/en/publications/Publications/1103_GUI_IGRA.pdf.
89. Santin M., Muñoz L., Rigau D. Interferon-γ release assay for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: A systematic review and meta-analysis. PLoS One 2012, 7:e32482.
90. Ruiz Manzano J., Blanquer R., Calpe J.L., Caminero J.A., Caylá J., Dominguez J.A., et al. Normativa SEPAR. Diagnóstico y tratamiento de la tuberculosis. Arch Bronconeumol 2008, 44:551-566.
91. Greenberg J.D., Reddy S.M., Schloss S.G., Kurucz O.S., Bartlett S.J., Abramson S.B., et al. Comparison of an in vitro tuberculosis interferon-γ assay with delayed-type hypersensitivity testing for detection of latent Mycobacterium tuberculosis: a pilot study in rheumatoid arthritis. J Rheumatol 2008, 35:770-775.
92. Inanc N., Aydin S.Z., Karakurt S., Atagunduz P., Yavuz S., Direskeneli H. Agreement between Quantiferon-TB gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2009, 36:2675-2681.
93. Bocchino M., Matarese A., Bellofiore B., Giacomelli P., Santoro G., Balato N., et al. Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur J Clin Microbiol Infect Dis 2008, 27:907-913.
94. Pratt A., Nicholl K., Kay L. Use of QuantiFERON TB Gold test as a part of a screening programme in patients with RA under consideration for treatment with anti-TNF-alpha agents: The Newcastle (UK) experience. Rheumatology (Oxford) 2007, 46:1035-1036.
95. Takahashi H., Shigehara K., Yamamoto M., Suzuki C., Naishiro Y., Tamura Y., et al. Interferon gamma assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration. Rheumatol Int 2007, 27:1143-1148.
96. Vassilopoulos D., Stamoulis N., Hadziyannis E., Archimandritis A.J. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. J Rheumatol 2008, 35:1464.
97. Matulis G., Juni P., Villiger P.M., Gadola S.D. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases performance of a Mycobacterium tuberculosis antigen specific IFN-gamma assay. Ann Rheum Dis 2008, 67:84-90.
98. Cobanoglu N., Ozcelik U., Kalyoncu U., Ozen S., Kiraz S., Furcan N. Interferon-gamma assays for the diagnosis of tuberculosis infection before using tumour necrosis factor-alpha blockers. Int J Tuberc Lung Dis 2007, 11:117-1182.
99. Sellam J., Hamdi H., Roy C., Baron G., Leman M., Puechal X. Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis 2007, 66:1610-1615.
100. Dominguez J., Latorre I., Altet N., Mateo L., de Souza Galvao M.L., Ruiz-Manzano J., et al. IFN-gamma release assay to diagnose TB infection in the immunocompromised individual. Expert Rev Respir Med 2009, 3:309-327.
101. Van Zyl-Smit R.N., Pai M., Peprah K., Meldau R., Kieck J., Juritz J., et al. Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. Am J Respir Crit Care Med 2009, 180:49-58.
102. Vilaplana C., Ruiz-Manzano J., Gil O., Cuchillo F., Montane E., Singh M., et al. The tuberculin skin test increases the responses measured by T cell interferon-gamma release assays. Scand J Immunol 2008, 67:610-617.
103. Papay P., Primas C., Eser A., Novacek G., Winkler S., Frantal S., et al. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-a inhibitors. Aliment Pharmacol Ther 2012, 36:858-865.
104. Chen D.Y., Shen G.H., Chen Y.M., Chen H.H., Hsieh C.W., Lan J.L. Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFa inhibitors: The utility of IFNg assay. Ann Rheum Dis 2012, 71:231-237.
105. Hatemi G., Melikoglu M., Ozbakir F., Tascilar K., Yazici H. Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor-alpha antagonists. Arthritis Res Ther 2012, 14:R147.
106. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000, 161(4 Pt 2):S221-S247.
107. Horsburgh C.R, Rubin E.J. Clinical practice. Latent tuberculosis infection in the United States. N Engl J Med 2011, 364:1441.
108. Update: Adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR Morb Mortal Wkly Rep 2003, 52:735. Centers for Disease Control and Prevention (CDC), American Thoracic Society.
109. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: Five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ 1982, 60:555.
110. Comstock G.W. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?. Int J Tuberc Lung Dis 1999, 3:847.
111. Nolan C.M., Goldberg S.V., Buskin S.E. Hepatotoxicity associated with isoniazid preventive therapy: A 7-year survey from a public health tuberculosis clinic. JAMA 1999, 281:1014.
112. Villarino M.E., Ridzon R., Weismuller P.C., Elcock M., Maxwell R.M., Meador J., et al. Rifampin preventive therapy for tuberculosis infection: Experience with 157 adolescents. Am J Respir Crit Care Med 1997, 155:1735.
113. Menzies D., Long R., Trajman A., Dion M.J., Yang J., Al Jahdali H., et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: A randomized trial. Ann Intern Med 2008, 149:689.
114. Jiménez-Fuentes M.A., de Souza-Galvao M.L., Mila Augé C., Solsona Peiró J., Altet-Gómez M.N. Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population. Int J Tuberc Lung Dis 2013, 17:326-332.
115. Pho M.T., Swaminathan S., Kumarasamy N., Losina E., Ponnuraja C., Uhler L.M., et al. The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: A trial-based analysis. PLoS One 2012, 7:e36001.
116. Paluch-Oleś J., Magryś A., Kozioł-Montewka M., Koszarny A., Majdan M. Identification of latent tuberculosis infection in rheumatic patients under consideration for treatment with anti-TNF-α agents. Arch Med Sci 2013, 9:112-117.
117. Nordgaard-Lassen I., Dahlerup J.F., Belard E., Gerstoft J., Kjeldsen J., Kragballe K., et al. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Dan Med J 2012, 59:C4480. Danish Society for Gastroenterology.
118. Wang L., Turner M.O., Elwood R.K., Schulzer M., FitzGerald.J.M. A meta-analysis of the effect of Bacille Calmette Guérin vaccination on tuberculin skin test measurements. Thorax 2002, 57:804-809.
119. Casas S., Andreu A., Juanola X., Bordas X., Alcaide F., Moure R., et al. Diagnosis of tuberculosis infection by tuberculin skin test and a whole-blood interferon-(release assay in patients considered for anti-tumor necrosis factor-α therapy. Diagn Microbiol Infect Dis 2011, 71:57-65.
120. Fraser A., Paul M., Attamna A., Leibovici L. Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: systematic review. Int J Tuberc Lung Dis 2006, 10:19-23.
121. Winthrop K.L., Weinblatt M.E., Daley C.L. You can't always get what you want, but if you try sometimes (with two tests-TST and IGRA-for tuberculosis) you get what you need. Ann Rheum Dis 2012, 71:1757-1760.